2024 Global Insurance Outlook: Implications for the Biotechnology Sector

How shifting insurance market dynamics are reshaping risk and opportunity in life sciences

Executive Summary

The 2024 global insurance outlook from Deloitte highlights an industry undergoing fundamental transformation. In the face of macroeconomic volatility, climate change, and technological disruption, insurers are shifting from reactive risk transfer toward proactive risk prevention and mitigation. For the biotechnology industry, these changes carry distinct implications: from pricing pressures on clinical trial liability coverage to new opportunities for partnerships in managing emerging risks like cyber threats and environmental liability. This article synthesizes the report’s key findings and examines their specific impact on biotechnology research, development, and commercialization.

Introduction

The biotechnology sector operates at the intersection of scientific innovation and high-stakes commercial risk. As genomic medicine, synthetic biology, and advanced therapies advance, so too do the complexities of insuring these activities. The 2024 global insurance outlook, published by Deloitte Insights, provides a comprehensive view of an industry that is itself adapting to a rapidly changing environment. For biotech executives, investors, and researchers, understanding these insurance market shifts is essential for strategic planning and operational resilience.

Insurance Market Background: A Sector Under Pressure

According to Deloitte’s analysis, the global insurance industry is facing a confluence of challenges. The report notes that “shifts in climate, technology, workforce, and customer/societal expectations combined with macroeconomic and geopolitical volatility” are compelling insurers to transform their business models. In the non-life sector, rising loss costs continue to outpace premium growth. Specifically, the report cites a US$26.9 billion net underwriting loss for US non-life insurers in 2022—the largest since 2011—driven by a 14.1% rise in incurred losses and loss adjustment expenses. This squeeze on profitability is prompting insurers to re-evaluate risk appetite, pricing, and product offerings.

These trends are particularly relevant to the biotechnology industry, which depends on comprehensive insurance for clinical development, manufacturing, and product commercialization. The hardening insurance market means higher premiums and stricter underwriting criteria for biotech companies, especially those undertaking high-risk trials or operating in litigious jurisdictions.

Research Findings: Deloitte’s Key Insights

Deloitte’s report identifies several transformative forces shaping the insurance landscape:

• From Risk Transfer to Risk Prevention: Insurers are increasingly looking to prevent losses rather than simply compensate for them. This is evident in the growing adoption of proactive risk management services, including loss prevention engineering, data analytics, and safety partnerships. For biotech firms, this shift could translate into more collaborative relationships with insurers, who may offer resources for improving lab safety, clinical trial monitoring, and supply chain resilience.
• The Rise of Generative AI and Data Analytics: The report emphasizes the potential of generative AI to “harvest actionable insights” from emerging data sources. Insurers are leveraging AI to improve underwriting accuracy, detect fraud, and personalize products. Biotechnology companies, with their vast repositories of clinical and operational data, are well-positioned to benefit from these developments—either as users or as partners in data-sharing initiatives.
• Customer-Centricity and Cultural Change: Deloitte argues that insurers must embrace enterprisewide cultural change, breaking down silos and focusing on customer experience. For biotech, this could mean more tailored insurance products that reflect the unique risk profiles of different research areas, from gene editing to digital health.
• Addressing the Protection Gap: The report underscores the concern over “vast uninsured and underinsured populations.” In a biotech context, this relates to the insurability of novel therapeutic categories and emerging risks such as synthetic biology-related liability. Insurers may develop new coverage mechanisms to support innovation while managing systemic risk.

Industry Impact: Implications for Biotechnology Companies

The 2024 insurance outlook carries several direct implications for the biotechnology industry:

• Higher Costs and Underwriting Scrutiny: With insurers seeking to restore profitability, biotech companies can expect more rigorous underwriting and higher premiums for clinical trial insurance, product liability, and property coverage. Companies with robust risk management frameworks will be better positioned.
• Enhanced Risk Management Opportunities: The shift toward loss prevention could benefit biotech firms that adopt proactive safety measures. Insurers may reward lower-risk behaviors with premium discounts and technical support.
• Cyber Risk and Data Security: The report’s emphasis on cybercrime is particularly salient for biotech, as the industry is a prime target for intellectual property theft and data breaches. Specialized cyber insurance products will become increasingly important.
• Climate and Environmental Liability: Biotechnology’s role in sustainable manufacturing and environmental solutions could intersect with insurers’ growing concerns about climate risk. Companies developing climate-positive technologies may find favorable insurance conditions.

Clinical and Regulatory Perspective

From a clinical and regulatory standpoint, the insurance market’s evolution affects the entire drug development lifecycle. The rising cost of clinical trial insurance may constrain research budgets, particularly for early-stage firms. Additionally, regulatory bodies are paying greater attention to insurance availability as a proxy for financial responsibility in advanced therapies. The Deloitte report notes that insurers are expected to demonstrate “sound ethical and financial stewardship,” which could align with the biotech industry’s own emphasis on patient safety and evidence-based medicine.

Moreover, the development of precision therapies—such as gene and cell therapies—poses new valuation challenges for insurers. The high upfront costs and durable treatment effects of these modalities require novel actuarial approaches. Biotech companies should engage with insurers early to design coverage that reflects the long-term value of their products.

Future Outlook: 2024–2034

Looking ahead, the convergence of insurance and biotechnology is likely to deepen. The next decade could see the emergence of parametric insurance products tied to clinical outcomes, real-time data sharing between biotech firms and insurers, and AI-driven risk modeling that incorporates genomic and real-world evidence. Sustainability-linked insurance, covering environmental risks, may also expand as biotech contributes to the circular bioeconomy.

Deloitte’s report anticipates that insurers will continue to evolve from “financial safety nets” to proactive “risk prevention partners.” For biotech, this evolution offers an opportunity to align insurance strategies with long-term innovation goals. Companies that proactively adapt to these changes will not only manage costs but also gain a competitive edge.

Key Takeaways for the Biotechnology Industry

• The 2024 global insurance outlook signals a harder market with higher premiums and stricter underwriting.
• Insurers are shifting toward risk prevention, offering opportunities for biotech companies to collaborate on safety and resilience.
• Generative AI and advanced data analytics are becoming central to insurance innovation, including in life sciences.
• Biotech companies should proactively manage cyber, clinical, and environmental risks to secure favorable coverage.
• New insurance models may emerge to support advanced therapies and sustainable technologies, encouraging long-term innovation.

Conclusion

The insurance industry is at a pivotal moment, and its transformation will reverberate across the biotechnology sector. By understanding the trends outlined in Deloitte’s 2024 global insurance outlook, biotech stakeholders can navigate a complex risk environment and build partnerships that support both scientific progress and financial stability. The future of biotech is not just about breakthrough science—it also depends on the resilience of the broader risk ecosystem.

Source

Deloitte Insights. (2024). 2024 global insurance outlook.